Maravai Q1 revenue $244.3M (+65% YoY); net income $146.9M; raises FY22 guidance

MARAVAI LIFESCIENCES HOLDINGS, INC.

2022-Q1 EPS reported $0.50 revenue$244,293,000

Record Q1 revenue $244.3M, up 65% YoY; Nucleic Acid Production $223.7M (+80%).
Net income $146.9M (+95% YoY); Adjusted EBITDA $187.0M (77% margin).
Nucleic Acid Production base business (ex-COVID CleanCap) revenue grew 55% YoY.
Full-year 2022 revenue guidance reaffirmed; Adjusted EBITDA and EPS guidance raised.
Deborah Barbara appointed Vice President, Business Development and Strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.